News About: Pharm. Industry
“Korean pharmaceutical companies have high chances to succeed in Russia”
President Alexey Repik(39) of the Russia’s top pharmaceutical company, R-PHARM, took a 4-day trip to Korea for 4 days from the 4th to 7th.
During the trip, he had in-depth discussions about creation of business model...
NHIS recorded largest collective surplus of KRW 17 trillion
Managed by the National Health Insurance Corporation(NHIS), the National Health Insurance budget is reaching for collective KRW 17 trillion gains.
According to the data provided by the 1st NHIS Regular Board Meeting ...
SK Biopharmaceuticals’ new epilepsy drug increases expectation for US FDA approvalA SK Biopharmaceuticals’ new epilepsy drug has been increasingly expected to acquire immediate approval from the U.S. FDA.
According to the industry concerned on the 15th, ‘YK...
|
What are domestic potential drugs to be exported globally?
Both pharmaceutical companies and biopharmaceutical ventures are actively researching and developing new drugs having potentials to be expanded into the global market. In particular, technological exports are expected...
KRW 1.86 trillion cashable assets by listed pharmaceutical companies
Cashable assets owned by listed pharmaceutical companies have continuously increased.
According to the Yakup Shinmoon’s(www.yakup.com) analysis result of the 2015 audit reports turned in by KOSPI and KOSDAQ listed ph...
Baraclude generics land large hospitals in series
As a series of Baraclude generics have landed in large hospitals, they have started to create competitions against the original product.
According to the industry concerned on the 14th, Asan Medical Center has recen...
1 of 4 listed pharmaceutical companies have ‘unsound’ financial structures
1 of 4 listed pharmaceutical companies were indicated to have poor financial status with over 100% debt ratios.
In addition, Myungmoon Pharm and JW Shinyak exceeded 200% in the ratio while Sama Pharm was observed to ...
Unstoppable listed pharmaceutical companies in 2015, solidifying both internally and externally
In 2015, listed pharmaceutical companies were observed to bear satisfactory fruits both internally and externally. Particularly, their sales growth rate went over double of their profit growth rate.
According to the ...
Biopharmaceutical investment only reaching 1/10 of other competing countries
After the Korea Exchange created the ‘Exceptional Listing Clause through Technology Evaluation’ on December 2005, the total 27 biotechnology companies have acquired approval to go public through it until the end of 20...
Corporate partition, trend among listed pharmaceutical companies
Ildong Pharmaceutical has decided to divide its company including its holding company ‘Ildong Holdings’ into 4 business units.
The Ildong Pharmaceutical’s partition is evaluated as a different meaning from other top ...
